全文获取类型
收费全文 | 205468篇 |
免费 | 2927篇 |
国内免费 | 152篇 |
专业分类
耳鼻咽喉 | 1443篇 |
儿科学 | 7368篇 |
妇产科学 | 3776篇 |
基础医学 | 20999篇 |
口腔科学 | 3401篇 |
临床医学 | 14930篇 |
内科学 | 37535篇 |
皮肤病学 | 1645篇 |
神经病学 | 19016篇 |
特种医学 | 9388篇 |
外科学 | 31149篇 |
综合类 | 2428篇 |
一般理论 | 21篇 |
预防医学 | 21538篇 |
眼科学 | 3233篇 |
药学 | 11851篇 |
中国医学 | 816篇 |
肿瘤学 | 18010篇 |
出版年
2024年 | 43篇 |
2023年 | 381篇 |
2022年 | 879篇 |
2021年 | 1543篇 |
2020年 | 876篇 |
2019年 | 1269篇 |
2018年 | 23241篇 |
2017年 | 18175篇 |
2016年 | 20307篇 |
2015年 | 2069篇 |
2014年 | 2327篇 |
2013年 | 2658篇 |
2012年 | 9795篇 |
2011年 | 23879篇 |
2010年 | 20201篇 |
2009年 | 12715篇 |
2008年 | 21468篇 |
2007年 | 23588篇 |
2006年 | 2269篇 |
2005年 | 3677篇 |
2004年 | 4671篇 |
2003年 | 5425篇 |
2002年 | 3442篇 |
2001年 | 377篇 |
2000年 | 477篇 |
1999年 | 258篇 |
1998年 | 329篇 |
1997年 | 328篇 |
1996年 | 166篇 |
1995年 | 162篇 |
1994年 | 159篇 |
1993年 | 103篇 |
1992年 | 82篇 |
1991年 | 117篇 |
1990年 | 147篇 |
1989年 | 97篇 |
1988年 | 66篇 |
1987年 | 55篇 |
1986年 | 34篇 |
1985年 | 44篇 |
1984年 | 35篇 |
1983年 | 33篇 |
1982年 | 39篇 |
1980年 | 52篇 |
1974年 | 23篇 |
1938年 | 60篇 |
1937年 | 25篇 |
1934年 | 30篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
Francisca Morgado Mariana Batista Ana Moreno Inês Coutinho 《Pediatric dermatology》2021,38(1):191-193
We present a 6‐year‐old girl with skin hyperpigmentation, leukoplakia, and onychodystrophy, the classic mucocutaneous triad usually associated with dyskeratosis congenita. The patient also had premature graying of the hair, bone marrow failure, hepatitis, exudative retinopathy, osteopenia with multiple long bone fractures, and intracranial calcifications and brain cysts. Coats plus syndrome is a rare disease with a clinical and genetic overlap with dyskeratosis congenita. This disease is reviewed, with a focus on the pathogenesis of the genetic anomalies and its background as a telomere biology disorder. 相似文献
12.
13.
N. S. Hari Narayana Moorthy Sergio F. Sousa Maria J. Ramos Pedro A. Fernandes 《Medicinal chemistry research》2016,25(7):1340-1357
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets. 相似文献
14.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
15.
Ana Lopez Alonso 《Platelets》2015,26(4):317-323
AbstractWhile the interactions between Gram-positive bacteria and platelets have been well characterized, there is a paucity of data on the interaction between other pathogens and platelets. However, thrombocytopenia is a common feature with many infections especially viral hemorrhagic fever. The little available data on these interactions indicate a similarity with bacteria-platelet interactions with receptors such as FcγRIIa and Toll-Like Receptors (TLR) playing key roles with many pathogens. This review summarizes the known interactions between platelets and pathogens such as viruses, fungi and parasites. 相似文献
16.
17.
18.
19.
20.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献